Next Article in Journal
Anti-Trichomonas vaginalis Activity of Triterpenes from Tagetes nelsonii Greenm
Previous Article in Journal
Enhanced Skin Permeation of Diclofenac Sodium Using Mango Seed Kernel Starch Nanoparticles
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Onodera et al. Prognostic Factors and Talaporfin Sodium Concentration in Photodynamic Therapy for Recurrent Grade 4 Glioma. Pharmaceuticals 2025, 18, 583

1
Faculty of Advanced Techno-Surgery (FATS), Institute of Advanced Biomedical Engineering and Science, Tokyo Women’s Medical University, 8-1 Kawada-Cho, Shinjuku, Tokyo 162-8666, Japan
2
Department of Pharmacy, Tokyo Women’s Medical University, 8-1 Kawada-Cho, Shinjuku, Tokyo 162-8666, Japan
3
Department of Hygiene and Public Health, Tokyo Women’s Medical University, 8-1 Kawada-Cho, Shinjuku, Tokyo 162-8666, Japan
4
Graduate School of Public Health, Shizuoka Graduate University of Public Health, 4-27-2 kita Ando, Aoi-ku, Shizuoka, Shizuoka 420-0881, Japan
5
Department of Neurosurgery, Tokyo Women’s Medical University, 8-1 Kawada-Cho, Shinjuku, Tokyo 162-8666, Japan
6
Center for Advanced Medical Engineering Research and Development, Kobe University, 1-5-1 Minatojima Minamimachi, Chuo-Ku, Kobe, Hyogo 650-0047, Japan
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2025, 18(10), 1586; https://doi.org/10.3390/ph18101586
Submission received: 29 September 2025 / Accepted: 30 September 2025 / Published: 21 October 2025

Error in Table

In the original publication [1], there were mistakes in a part of Table 2, Section 2.5, and the label of Table 3. In Table 2, errors present in the data shown under “Recurrence” were identical to those under “Newly Diagnosed”. The corrected Table 2 appears below.
The values in Section 2.5 of the text did not match those in Table 3. We have replaced the first paragraph in Section 2.5 with the paragraph below, in which the numerical values have been corrected, as shown in Table 3. In addition, the label of the right-hand group in Table 3 was incorrect; the correct label is “Recurrence.” The corrected Table 3 appears below. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

2.5. Analysis of Clinical Factors in the High vs. Low Intratumoral TS Concentration Groups

Among the 82 patients for whom intratumoral TS concentration was measured, the newly diagnosed group consisted of 41 patients (high concentration, 51.2%; low concentration, 48.8%) with a mean age of 60.7 years (SD: 12.2 years) and 61.3 years (SD: 11.9 years), respectively.
Similarly, the recurrent group included 41 patients (high concentration, 51.2%; low concentration, 48.8%) with a mean age of 47.6 years (SD: 14.2 years) and 53.6 years (SD: 10.5 years), respectively.
No significant differences in age or sex were observed between the high- and low-concentration groups (age, Newly Diagnosed p = 0.884 and Recurrence p = 0.5843, and sex, Newly Diagnosed p = 0.837 and Recurrence p = 0.5843, respectively). Additionally, no significant differences were found in tumor location, genetic mutations, benzodiazepine use, or smoking history, suggesting that no specific factors were associated with TS concentrations (Table 3).
Table 2. Analysis of risk factors among the two groups of patients who underwent PDT between January 2017 and March 2024: newly diagnosed (n = 74) and recurrent (n = 97).
Table 2. Analysis of risk factors among the two groups of patients who underwent PDT between January 2017 and March 2024: newly diagnosed (n = 74) and recurrent (n = 97).
Newly DiagnosedRecurrence
Hazard Ratio (95% CI)p-ValueHazard Ratio (95% CI)p-ValueHazard Ratio (95% CI)p-ValueHazard Ratio (95% CI)p-Value
Age1.02 (0.99–1.04) 0.261.02 (0.99–1.05)0.271.01 (0.99–1.03)0.222.03 (0.81–5.93) 0.50
Male vs. female sex1.35 (0.62–2.94)0.44 1.08 (0.62–1.88) 0.45
KPS0.98 (0.95–1.00) 0.0970.96 (0.93–0.99) 0.010.09 (0.02–0.33)0.00030.96 (0.95–0.99)0.0008
Alb1.51 (0.51–4.48)0.453.68 (1.05–13.76)0.0472.22 (0.88–5.84)0.0902.13 (0.81–5.93)0.13
Total cholesterol1.00 (0.98–1.01)0.59 1.00 (0.99–1.01) 0.40
Benzodiazepine2.36 (0.81–6.88)0.153.06 (0.96–9.76)0.0590.77 (0.34–1.72)0.520.77 (0.34–1.74) 0.52
Smoking1.57 (0.70–3.53)0.291.58 (0.67–3.73) 0.31.07 (0.64–1.79)0.801.21 (0.67–2.19) 0.53
Localization
   Temporal vs. not temporal0.50 (0.22–1.11) 0.079 1.00 (0.56–1.78) 0.99
   Frontal vs. not frontal1.14 (0.51–2.56) 0.75 0.72 (0.43–1.20) 0.20
   Parietal vs. not parietal1.32 (0.53–3.31)0.56 1.36 (0.72–2.53)0.35
Table 3. Comparison between the newly diagnosed and recurrent groups based on median tissue TS concentration.
Table 3. Comparison between the newly diagnosed and recurrent groups based on median tissue TS concentration.
Newly Diagnosed Recurrence
Mean TS Concentration
≤0.16333
Mean TS Concentration
>0.16333
Mean TS Concentration
≤0.0883
Mean TS Concentration
>0.0883
n = 21
51.2 (%)
n = 20
48.8 (%)
p-Valuen = 21
51.2 (%)
n = 20
48.8 (%)
p-Value
Male vs. female13 (31.7%)/8 (19.5%)13 (31.7%)/7 (17.1%)0.83713 (31.7%)/8 (19.5%)14 (34.2%)/6 (14.6%)0.5843
Age, mean ± SD60.7 ± 12.261.3 ± 11.90.88447.6 ± 14.253.6 ± 10.50.5843
Left vs. right (excluded bilateral case)11 (31.4%)/7 (20.0%)6 (17.1%)/11 (31.4%)0.124510 (26.3%)/9 (23.7%)6 (15.8%)/13 (34.2%)0.1869
Pathological diagnosis
   Mean MIB-1 ± SD28.9 ± 11.922.1 ± 11.50.060721.3 ± 15.422.0 ± 15.50.8886
   ATRX intact vs. loss20 (51.2%)/0 (0%)18 (46.2%)/1 (2.6%)0.22612 (30.8%)/7 (18.0%)16 (39.0%)/4 (9.7%)0.2407
   P53 (+) vs. (−)4 (9.76%)/17 (41.5%)6 (14.6%)/14 (34.2%)0.41346 (15.0%)/14 (35.0%)7 (17.0%)/13 (31.7%)0.7356
   IDH (+) vs. (−)0 (0%)/21 (51.2%)1 (2.4%)/19 (46.3%)0.2265 (12.5%)/15 (37.5%)4 (9.7%)/16 (39.0%)0.7047
Part
   Temporal vs. not temporal7 (17.1%)/14 (34.2%)9 (22.0%)/11 (26.8%)0.44358 (19.5%)/13 (31.7%)5 (12.2%)/15 (36.6%)0.366
   Frontal vs. not frontal11 (26.8%)/10 (24.4%)8 (19.5%)/12 (29.3%)0.42617 (17.1%)/14 (34.2%)8 (19.5%)/12 (29.3%)0.6577
   Parietal vs. not parietal2 (4.9%)/19 (46.3%)2 (4.9%)/18 (43.9%)0.9595 (12.2%)/16 (39.0%)5 (12.2%)/15 (36.6%)0.9293

Reference

  1. Onodera, M.; Kitahara, S.; Sato, Y.; Kawamata, T.; Muragaki, Y.; Masamune, K. Prognostic Factors and Talaporfin Sodium Concentration in Photodynamic Therapy for Recurrent Grade 4 Glioma. Pharmaceuticals 2025, 18, 583. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Onodera, M.; Kitahara, S.; Sato, Y.; Kawamata, T.; Muragaki, Y.; Masamune, K. Correction: Onodera et al. Prognostic Factors and Talaporfin Sodium Concentration in Photodynamic Therapy for Recurrent Grade 4 Glioma. Pharmaceuticals 2025, 18, 583. Pharmaceuticals 2025, 18, 1586. https://doi.org/10.3390/ph18101586

AMA Style

Onodera M, Kitahara S, Sato Y, Kawamata T, Muragaki Y, Masamune K. Correction: Onodera et al. Prognostic Factors and Talaporfin Sodium Concentration in Photodynamic Therapy for Recurrent Grade 4 Glioma. Pharmaceuticals 2025, 18, 583. Pharmaceuticals. 2025; 18(10):1586. https://doi.org/10.3390/ph18101586

Chicago/Turabian Style

Onodera, Mikoto, Shuji Kitahara, Yasuto Sato, Takakazu Kawamata, Yoshihiro Muragaki, and Ken Masamune. 2025. "Correction: Onodera et al. Prognostic Factors and Talaporfin Sodium Concentration in Photodynamic Therapy for Recurrent Grade 4 Glioma. Pharmaceuticals 2025, 18, 583" Pharmaceuticals 18, no. 10: 1586. https://doi.org/10.3390/ph18101586

APA Style

Onodera, M., Kitahara, S., Sato, Y., Kawamata, T., Muragaki, Y., & Masamune, K. (2025). Correction: Onodera et al. Prognostic Factors and Talaporfin Sodium Concentration in Photodynamic Therapy for Recurrent Grade 4 Glioma. Pharmaceuticals 2025, 18, 583. Pharmaceuticals, 18(10), 1586. https://doi.org/10.3390/ph18101586

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop